Table 2.
Dose–response relationships of TP substitution mutants in presence of PKA activation or inhibition
| Receptor | log EC50a untreated | log EC50a when PKA activated | log EC50a when PKA inhibited |
|---|---|---|---|
| TPα wt | −7.24 ± 0.08 | – | – |
| Ser239A | −7.18 ± 0.22 | −7.03 ± 0.27 | −8.36 ± 0.30 |
| Ser324A | −8.10 ± 0.18 | −8.09 ± 0.23 | −8.00 ± 0.19 |
| Ser329A | −7.16 ± 0.19 | −7.14 ± 0.13 | −8.15 ± 0.11 |
| Ser331A | −5.63 ± 0.17 | −5.60 ± 0.20 | −5.54 ± 0.20 |
a
log EC50 = log molar concentration of agonist U46619 that produces 50% of maximal peak calcium mobilization response for TP receptors and TP substitution mutant receptors. Boldface values differ from reference value, untreated wild type (P < 0.05).